Your browser doesn't support javascript.
loading
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
Wilbaux, Mélanie; Demanse, David; Gu, Yi; Jullion, Astrid; Myers, Andrea; Katsanou, Vasiliki; Meille, Christophe.
Affiliation
  • Wilbaux M; Pharmacometrics, Novartis, Basel, Switzerland.
  • Demanse D; Early Development Analytics, Novartis, Basel, Switzerland.
  • Gu Y; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Cambridge, USA.
  • Jullion A; Early Development Analytics, Novartis, Basel, Switzerland.
  • Myers A; Clinics, Novartis, Shanghai, China.
  • Katsanou V; Clinical Operations, Novartis, Basel, Switzerland.
  • Meille C; Early Development Analytics, Novartis, Basel, Switzerland.
CPT Pharmacometrics Syst Pharmacol ; 11(8): 1122-1134, 2022 08.
Article in En | MEDLINE | ID: mdl-35728123
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2022 Type: Article Affiliation country: Switzerland
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2022 Type: Article Affiliation country: Switzerland